文献速递心力衰竭与心肌病

维利西呱对射血分数降低心衰患者死亡率的影响:VICTOR试验

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
PubMed 文献 · Eur Heart J · 2026-01-01

VICTOR试验纳入6105例病情稳定的射血分数降低心衰门诊患者,随机接受维利西呱或安慰剂。中位随访19.7个月,维利西呱组心血管死亡(HR 0.83,95%CI 0.71-0.97;

要点

  • 心脏性猝死和心衰相关死亡亦降低,获益在亚组中一致。

核心结论

  • 在病情稳定、治疗充分的心衰伴射血分数降低门诊患者中,维利西呱与心血管死亡及全因死亡率降低相关。

研究设计与样本

  • VICTOR(NCT05093933)为双盲、安慰剂对照、随机试验,纳入6105例无近期恶化的射血分数降低心衰门诊患者,随机接受维利西呱或安慰剂。
  • 本分析主要终点为预设的次要终点心血管死亡,同时评估全因死亡、心脏性猝死和心衰相关死亡。

主要发现

  • 包括基线治疗在内的各亚组死亡率降低一致,且在不同基线NT-proBNP水平中均观察到一致的心血管和全因死亡获益。

临床怎么用

  • 对于病情稳定、已接受优化治疗的心衰伴射血分数降低门诊患者,维利西呱可考虑用于降低心血管死亡和全因死亡风险。
  • 治疗决策时应结合患者基线特征及耐受性,并关注其降低心脏性猝死和心衰相关死亡的潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In the VICTOR trial (NCT05093933), vericiguat was neutral for the primary composite endpoint of cardiovascular death or hospitalization for heart failure (HF). VICTOR was powered to independently assess cardiovascular death. This study reports detailed analysis on the effects of vericiguat on mortality. METHODS: VICTOR, a double-blind, placebo-controlled, randomized trial, enrolled 6105 ambulatory patients with HF and reduced ejection fraction (HFrEF) without recent worsening and randomized them to vericiguat or placebo. The main outcome for this analysis was the pre-specified secondary endpoint of cardiovascular death. All-cause death, sudden cardiac death, and death related to HF were also assessed. RESULTS: Over a median of 19.7 months (inter-quartile range 14.6-25.4), cardiovascular deaths occurred in 292 patients (5.7 deaths per 100 patient-years) and 346 patients (6.8 deaths per 100 patient-years) in the vericiguat and placebo groups, respectively (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.71-0.97; P = .020). Risk of death from any cause was lower with vericiguat vs placebo (377 [7.3 deaths per 100 patient-years] vs 440 [8.6 deaths per 100 patient-years]; HR 0.84, 95% CI 0.74-0.97; P = .015). Sudden cardiac death and HF-related deaths were lower with vericiguat vs placebo (1.6 vs 2.2 events per 100 patient-years; HR 0.75, 95% CI 0.56-0.99; P = .042 and 1.7 vs 2.4 events per 100 patient-years; HR 0.71, 95% CI 0.54-0.94; P = .016, respectively). Lower mortality rates were consistent across subgroups including baseline therapy. Consistent cardiovascular and all-cause mortality benefit was seen across baseline N-terminal pro-B-type natriuretic peptide levels. CONCLUSIONS: In ambulatory well-treated participants with HFrEF, vericiguat was associated with clinically meaningful reductions in the key secondary outcome of cardiovascular death, as well as all-cause mortality.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Butler, Fioretti, McMullan, et al. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Eur Heart J. 2026. PMID: 40884032. doi:10.1093/eurheartj/ehaf655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。